Pregabalin Capsule
Product Images NDC 70518-4579

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 70518-4579). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Mm1 (Pregabalin 75mg 70518 4579 00)

Pregabalin Capsule C-V 75 mg oral capsules packaging label from RemedyRepack Inc. The label states a quantity of 90 capsules, NDC 70518-4579-00, and includes cautionary and storage instructions along with repackager contact details. Manufacturer information for Torrent Pharma Inc. is also present.*

FDA Label Image

Image (C3bcdf74 0ed9 439b 8f44 3f07e5c04e46 01)

A mathematical formula for calculating creatinine clearance (CLCr) showing the relationship between age, weight, serum creatinine, and a factor for female patients. The formula is presented with variables and constants in standard mathematical notation.*

FDA Label Image

Image (C3bcdf74 0ed9 439b 8f44 3f07e5c04e46 02)

Chemical structure diagram of pregabalin showing its molecular configuration with labeled functional groups including a carboxylic acid and an amino group.*

FDA Label Image

Image (C3bcdf74 0ed9 439b 8f44 3f07e5c04e46 03)

A line graph showing the percent of patients improved on the y-axis against percent improvement in pain from baseline on the x-axis. The graph compares the efficacy of Pregabalin at different doses (200 mg three times a day, 100 mg three times a day, 25 mg three times a day) and placebo over varying levels of pain improvement.*

FDA Label Image

Image (C3bcdf74 0ed9 439b 8f44 3f07e5c04e46 04)

A line graph comparing the percent of patients improved against the percent improvement in pain from baseline. It features two lines representing Pregabalin 100 mg three times a day and placebo, showing patient response over varying pain improvement percentages.*

FDA Label Image

Image (C3bcdf74 0ed9 439b 8f44 3f07e5c04e46 05)

A line graph depicting percent improvement in pain from baseline versus percent of patients improved. It compares Pregabalin at doses of 75 mg, 150 mg, and 300 mg taken twice daily, and placebo, showing their relative effects on pain improvement percentages.*

FDA Label Image

Image (C3bcdf74 0ed9 439b 8f44 3f07e5c04e46 06)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline. The graph compares Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo over a range of improvement percentages from 0 to 100 on the x-axis and 0 to 100 percent of patients improved on the y-axis.*

FDA Label Image

Image (C3bcdf74 0ed9 439b 8f44 3f07e5c04e46 07)

A line graph showing the percent of patients improved by percent improvement in pain from baseline. It compares Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo groups, with patient improvement percentage on the vertical axis and percent improvement in pain on the horizontal axis.*

FDA Label Image

Image (C3bcdf74 0ed9 439b 8f44 3f07e5c04e46 08)

A bar graph showing reported rates (%) from two studies labeled E1 and E3. The x-axis lists groups including placebo and various doses (50 mg, 100 mg, 300 mg, 600 mg) with corresponding participant counts (N). The y-axis represents reported rates as percentages up to 60%. Some data points are marked to indicate statistical significance versus placebo.*

FDA Label Image

Image (C3bcdf74 0ed9 439b 8f44 3f07e5c04e46 09)

A line graph depicting the relationship between Pregabalin dose (mg/day) on the x-axis and median percent reduction in seizures (change from baseline) on the y-axis. The graph includes four study groups (E1BD, E2TID, E3BD, E3TID) represented by different markers, showing increasing seizure reduction with higher doses and accompanying p-values indicating statistical significance.*

FDA Label Image

Image (C3bcdf74 0ed9 439b 8f44 3f07e5c04e46 10)

A vertical bar chart showing responder rates (%) for three groups: Placebo, 2.5 mg/kg/day, and 10 mg/kg/day. The Y-axis ranges from 0 to 60%. Responder rates are 22.6% for Placebo (n=93), 29.1% for 2.5 mg/kg/day (n=103), and 40.6% for 10 mg/kg/day (n=96).*

FDA Label Image

Image (C3bcdf74 0ed9 439b 8f44 3f07e5c04e46 12)

A Kaplan-Meier survival curve graph illustrating the estimated percentage of subjects without LTR (loss to response) over a period of 180 days, comparing Pregabalin and placebo groups. The x-axis represents days, and the y-axis shows the estimated percentage of subjects without LTR, with Pregabalin consistently showing a higher survival rate than placebo.*

FDA Label Image

Image (C3bcdf74 0ed9 439b 8f44 3f07e5c04e46 13)

A line graph showing the percent of subjects improved over time, comparing Pregabalin and Placebo. The x-axis represents the percent improved from baseline to Week 12 BOCF, ranging approximately from >0 to 100. The y-axis indicates the percent of subjects improved, ranging from 0 to 100. The graph features two lines: a solid line for Pregabalin showing higher improvement percentages compared to the dashed line for Placebo.*

FDA Label Image

Image (C3bcdf74 0ed9 439b 8f44 3f07e5c04e46 14)

A line graph showing the percent of subjects improved over time, comparing Pregabalin and Placebo from baseline to Week 16 using BOCF analysis. The x-axis represents percent improved in increments up to 100, and the y-axis shows the percent of subjects improved, with Pregabalin consistently above Placebo.*

FDA Label Image

Image (Figure 9)

A line chart depicting data trends over a continuous variable, with four distinct lines represented in black and gray shades. Vertical lines mark specific points along the x-axis, suggesting key events or phases in the data. The chart includes a legend with four line styles but lacks axis labels or titles.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.